Rethinking Obesity: Novo Nordisk's Latest Initiative Urges Singaporeans to Treat, Not Blame
'Beyond the Scale' focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care.
Novo Nordisk's 'Beyond the Scale' initiative
Raise awareness of obesity as a chronic, multifactorial disease.
Reduce stigma and myths that hinder early care.
Encourage timely, evidence-based conversations with healthcare professionals.
Promote empathy and science within the medical community.
Support patients with tools to take charge of their health.
Visiting [www.truthaboutweight.sg] for factual resources, use a BMI measurement tool, and locate a nearest weight management healthcare professional.
Starting honest conversations with GPs, nurses, and pharmacists.
Sharing content to help dismantle myths and support loved ones on their health journeys.
SINGAPORE - Media OutReach Newswire - 27 June 2025 -Imagine a chronic disease affecting more than 600,000 peoplein Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This is the reality of obesity today. For many, outdated perceptions and delays in care have created barriers to support and treatment. Today, a new initiative is calling for a shift — to change how we think, talk about, and respond to obesity, through a lens of science, empathy, and early intervention."Just eat less." "Try harder." "It's a lifestyle choice." These are more than just phrases — they reflect a deeper misunderstanding of obesity. Today, a bold new initiative, seeks to challenge those misconceptions and open the door to a more compassionate, evidence-based conversation.launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, but as a complex, chronic disease. The initiative invites the public to go beyond — beyond stigma, beyond myths, beyond labels — and recognise obesity for what science confirms it to be: a multifactorial health condition that deserves understanding, early intervention, and clinical care.Led by global healthcare companyin collaboration with local healthcare professionals and patient advocates, "Beyond the Scale" is a disease awareness initiative aimed at driving a shift in how individuals, communities, and healthcare providers approach obesity management."We believe it's time to shift from blame to understanding," said. "Obesity affects 1 out of 9 people in Singapore, yet it's still too often seen as a matter of willpower. The reality is that obesity is a complex, chronic disease driven by biology, environment, and unequal access to care.It's time we treat it with the seriousness it deserves — and we are proud to lead that conversation and drive meaningful change through the "Beyond the Scale" initiative.The 2021–2022 National Population Health Survey reveals the highest obesity rate (15%) among adults aged 40 to 49, while 43.3% of residents aged 18 to 74 had abdominal obesity, which increases with age and peaks between 50 to 74 years.This is compounded by the fact that perceptions persist about obesity being a personal failing, discouraging individuals from seeking help, delaying diagnosis, and compounding the health burden on families and the healthcare system.Obesity significantly increases the risk of, all of which already place a growing strain on Singapore's healthcare infrastructure. The economic impact is substantial: in 2019, metabolic-risk related diseases, including obesity, diabetes, hypertension, CKD, and cardiovascular conditions, cost Singapore S$2.20 billion.Of this, S$642 million were healthcare expenditures, and excess weight alone accounted for an estimated S$261 million in annual medical and absenteeism costs.Without decisive public health action, these obesity-related comorbidities are poised to escalate into a major societal and economic burden."This is not just a personal issue — it's a public health priority," said"We know obesity changes how the body regulates appetite, energy storage, and metabolism. It's a disease, not a choice. Science supports this — and our response should reflect it."Obesity is not simply about calories in and out. Research confirms it involves neuroendocrine (hormonal), genetic, and psychosocial factors, making it both preventable and treatableStudies show that in Singapore, weight stigma is often driven by the belief that obesity is a personal failing, lack of willpower, or lifestyle choice leading to delayed treatment, reduced care-seeking, and poorer health outcomes, particularly in managing chronic conditions such as cardiovascular and kidney disease."Beyond the Scale" is more than a slogan — it is a call toTo move away from blame, appearance-based judgments, and oversimplified narratives, toward empathy, science, and sustained health. It is an urgent appeal to rethink, retrain, and rehumanise the way we support individuals living with obesity."The earlier we intervene, the better the outcomes," said"Obesity is not a character flaw. It's a disease. And it's time we responded with the same respect, science, and care we give every other chronic condition.""Beyond the Scale" aims to:Singaporeans can participate by:1. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.2. World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity 3. World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/ 4. Lee, Y. V., & Tan, N. C. (2014). Obesity in Singapore: An update. The Singapore Family Physician, 40(2), 11–16. https://cfps.org.sg/publications/the-singapore-family-physician/article/71_pdf 5. World Health Organization. (2024). Obesity and overweight..https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight As accessed on 22nd May 2025.6. Ministry of Health, Singapore. (2022). National Population Health Survey 2022 Report. https://isomer-user-content.by.gov.sg/3/28c3b8f9-9216-46be-8fc9-b614098666a9/nphs-2022-survey-report_final.pdf 7. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep. 2015 May;17(5):34. doi: 10.1007/s11906-015-0544-2. PMID: 25833456; PMCID: PMC4427189.8. Tan, V., Lim, J., Akksilp, K.The societal cost of modifiable risk factors in Singapore.23, 1285 (2023). https://doi.org/10.1186/s12889-023-16198-2 (2.2 Billion)9. Junxing C, Huynh VA, Lamoureux E, Tham KW, Finkelstein EA. Economic burden of excess weight among older adults in Singapore: a cross-sectional study. BMJ Open. 2022 Sep 16;12(9):e064357. doi: 10.1136/bmjopen-2022-064357. PMID: 36113947; PMCID: PMC9486358.10. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290.11. Goff AJ, Lee Y, Tham KW. Weight bias and stigma in healthcare professionals: a narrative review with a Singapore lens. Singapore Med J. 2023 Mar;64(3):155-162. doi: 10.4103/singaporemedj.SMJ-2022-229. PMID: 36876621; PMCID: PMC10071861.Hashtag: #NovoNordisk
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
"Beyond the Scale" campaign builds on Novo Nordisk's long-standing commitment to tackling chronic diseases. With over 100 years of experience advancing care for diabetes and more than 25 years of focused obesity research, Novo Nordisk is pioneering the medical management of obesity and the science of the GLP-1 hormone — a naturally occurring signal that regulates appetite and plays a key role in achieving sustained weight loss.
As part of its mission to drive long-term health outcomes, Novo Nordisk is also investing in scalable prevention efforts. Through the Cities for Better Health initiative — a global public-private partnership spanning over 50 cities — Novo Nordisk is working to reduce chronic disease risk in vulnerable urban communities. Its latest programme, the Childhood Obesity Prevention Initiative (COPI), delivers targeted interventions to promote healthier diets and physical activity among children aged 6–13 in underserved areas.
In Singapore and beyond, these initiatives reinforce Novo Nordisk's holistic approach: treating obesity with medicine and empathy today, while building healthier environments for the next generation.
For more information, visit novonordisk.sg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
3 hours ago
- Malay Mail
SST on outpatient care for foreign workers could backfire, say private GPs pushing for urgent exemption
KUCHING, June 29 — The Federation of Private Medical Practitioners' Associations, Malaysia (FPMPAM) has proposed for the government to fully exempt primary care services for foreign workers from the Sales and Services Tax (SST). FPMPAM president Dr Shanmuganathan Ganeson said that as an alternative, the government could implement a temporary moratorium on the tax to allow time to explore a fair and sustainable healthcare financing mechanism. 'We have formally submitted an appeal to the Ministry of Finance (MoF), urging an urgent exemption from the upcoming six per cent SST on primary healthcare services provided to foreign workers, scheduled to take effect on July 1,' he said in a statement. Dr Shanmuganathan said although the Foreign Workers Medical Examination Monitoring Agency (Fomena) screenings remained exempt, many foreign workers would still require outpatient care for common illnesses, injuries, and chronic conditions — essential services typically paid for out-of-pocket by the workers themselves, or arranged through employer or Third-Party Administrator (TPA) programmes. Under the new SST rules, such services would be taxed once a clinic's annual revenue exceeds RM1.5 million. Dr Shanmuganathan said: 'The foreign workers are already vulnerable and underserved, and the SST to basic medical treatment risks deterring them from seeking timely care, delaying diagnosis, and ultimately compromising public health. 'We are also concerned about the eight per cent SST on commercial property rentals, which would further escalate operating costs for clinics renting shoplots, medical suites, or office units. 'These taxes compound the strain on solo and small-group practices that have seen no fee adjustments for decades.' Dr Shanmuganathan also highlighted that the Federation of Malaysian Manufacturing (FMM) recently called for a broader reassessment of the SST expansion, citing its potential to harm the business environment and consumers. 'FPMPAM echoes this concern, urging the MoF to prioritise public health and service sustainability. 'FPMPAM also notes a policy anomaly where beauticians and cosmeticians, which are not related to essential health, now have no tax, whilst tax is imposed for essential health and medical services.' Nonetheless, Dr Shanmuganathan said the federation stood ready to work with the MoF to ensure that tax policies would not inadvertently undermine access to essential healthcare or threaten the survival of community clinics. — The Borneo Post
Malay Mail
3 hours ago
- Malay Mail
Health minister: Singapore to raise first-time blood donor age limit to 65 from 2026
SINGAPORE, June 29 — From January 1, 2026, the age limit for first-time blood donors in Singapore will be raised from 60 to 65, Health Minister Ong Ye Kung announced yesterday. According to Channel News Asia (CNA), Ong said the move aims to expand the donor pool amid rising demand and an ageing population. He also said the decision reflects longer life expectancy and data showing fewer adverse reactions among older donors. 'There is no reason to believe that once you cross 60 years old, suddenly the adverse reaction prevalence rate is going to shoot up,' he reportedly said at a World Blood Donor Day event yesterday. Singapore's new limit brings it in line with countries such as the United Kingdom and South Korea. Currently, only repeat donors can give blood beyond age 60, if they meet health criteria. The country's blood supply remains under pressure, with new donor numbers falling and demand increasing — over 35,000 patients required transfusions in 2023. Seasonal dips and past critical shortages, especially in Group O blood, have also posed challenges.
Malay Mail
7 hours ago
- Malay Mail
Cheap and risky: Stung by high prices, Americans turn to DIY weight-loss drugs from the grey market
Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved by FDA Drugmakers call trend dangerous and illicit Online community says it's filling gaps in broken system SAN FRANCISCO, June 29 — In what she calls the 'wild west' of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the US Food and Drug Administration. One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound. Spencer, 50, is not part of any drug trial but mixes the cocktails herself, using tiny doses that she believes are safe. The total cost is about US$50 (RM211) monthly, as little as one-tenth of what she would expect to pay their makers for full treatment. The drugs — glucagon-like peptide-1 (GLP-1) weight-loss medicines — are manufactured and shipped from China, according to the packaging. She orders them through online vendors. Spencer belongs to a fast-growing group of Americans turning to what many call the 'grey market' for obesity medicines, bringing cheap active ingredients from China often labelled as for research purposes, according to import data and social media postings. It's a trend that drugmakers Lilly and Novo Nordisk, which makes Wegovy, say is dangerous as well as illicit. Reuters tracked online forums and interviewed seven people who said they bought obesity medicines through this market, including an attorney in Arizona who works for a state insurance agency, a retired nurse in Illinois and a Type 1 diabetic in Louisiana, who said the medicine helped cut her insulin intake by more than half. For more than a year there has been demand for cheap Chinese-made powders, exacerbated by limited health insurance coverage in the US Buyers told Reuters the grey market received a boost from an FDA ruling last year that US compounding pharmacies — outsourcing facilities that create drugs in shortage — must stop selling obesity medicines more cheaply than the companies that developed them. Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44 per cent in January from the previous month, according to research by the Partnership for Safe Medicines, a public health group focused on the safety of prescription drugs. It said its findings are likely an undercount, because unregistered vendors may not disclose that their parcels contain medicines. Packages valued at less than US$800 that enter the US under the de minimis rule are not included in the data. Amy Spencer holds a number of vials containing components of obesity drugs, which were purchased through the grey market, a new market for obesity drugs that allows consumers to purchase medication materials from China and reconstitute them into injectable drugs, at her home in southern Missouri April 24, 2025. — Reuters pic Nearly three-quarters of US adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organisation KFF found only about 8 per cent say they have taken medicine for weight loss. Most of the grey market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them. Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to consulting firm Mercer. Many Americans have paid out of pocket for cheaper compounded drugs. Interest in taking small doses of the drugs has also spurred the online marketplace, buyers said. Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny. They swap advice for navigating the market, exchanging information on vendors, shipping and dosage, and sometimes clubbing together to cover the cost of testing the powders. One forum is called StairwayToGray. It has more than 21,000 members on Telegram and recently was gaining nearly 1,000 members weekly. It did not respond to Reuters' inquiries, and blocked access to the forum after receiving them. It has a website where it says it does not facilitate group purchases. 'This community is filling the gaps and being our own regulators, ensuring testing and access for everyone who needs it. Because you shouldn't have to choose between your health or your wallet,' it says. Spencer stores her stocks in her fridge and makes them up in the kitchen — carefully measuring sterile water, rolling the vial between her fingers until the powder dissolves, and drawing the liquid into a syringe before injecting it into her thigh or belly. She has lost 24 pounds. 'This is working so well for me. It's so easy. It's cheap,' said Spencer, who assumes her health plan wouldn't cover the drugs. 'I don't know what I would do without this medicine.' Amy Spencer poses for a portrait in a beveled bathroom mirror while holding a syringe and a vial that contained the components of obesity drugs, which she purchased through the grey market, a new market that allows consumers to purchase obesity medication materials from China and reconstitute them into injectable drugs, at her home in southern Missouri April 24, 2025. — Reuters pic 'Very dangerous' In February, 38 US state and territory attorney generals wrote the FDA seeking action against illegally sold weight-loss medicines, including 'research purposes only' ingredients from China. 'Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources... and pose risks of contamination and inclusion of foreign substances,' they said. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said unapproved drugs can have problems with sterility, purity and consistency. 'It can be very dangerous. You're playing the role of your own doctor, pharmacist, and FDA inspector,' he said. Of those interviewed, only Spencer reported any problems: She once got her math wrong and overdosed, resulting in several days of severe flu-like symptoms. Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, including those described as 'research use only.' 'We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same,' a Lilly spokesperson told Reuters. Novo Nordisk also said it continues to take action against entities that violate laws and regulations and put patient safety at risk. America's Poison Control agency, which maintains the nation's poison data surveillance system and monitors GLP-1 exposures, said it could not reliably track cases involving unregulated 'research chemical powders' because they are sold under various names and formulations. The FDA's goal is to stop illegal sales of pharmaceutical medicines at the border, said George Karavetsos, former director of the FDA's Office of Criminal Investigations and co-author of the imports study. But understanding the true nature and intended use of small parcels arriving from China can be difficult, and the FDA rarely seeks charges against consumers for personal use, he said. The FDA said it urges consumers to buy from licensed pharmacies and 'avoid products of unknown quality,' adding it was actively protecting consumers by intercepting illegal products at ports, and warning companies that market unapproved weight-loss medicines, including those mislabelled as 'for research purposes.' Although the forums show suppliers purportedly in China, Reuters was not able to verify where the drugs originate. None of the vendors responded to requests for comment. A Reddit spokesperson said the site prohibits facilitating transactions involving drugs and it had shut down a group found to be doing this. Telegram said it removes 'more than a million' instances of harmful content each day, but did not comment directly. Amy Spencer injects herself with obesity medication, which she purchased through the grey market, a new market for obesity drugs that allows consumers to purchase medication materials from China and reconstitute them into injectable drugs, at her home in southern Missouri April 24, 2025. — Reuters pic Microdose mistake Spencer has polycystic ovary syndrome and for years struggled with weight gain and hypertension. She decided to try obesity medicines after seeing claims on social media that microdosing them could give fewer side effects, and bought semaglutide, the active ingredient in Wegovy, from a compounding pharmacy for about US$200 per month. She started on one-fifth of the lowest dose. Within days, intermittent joint pain she often suffered had dissipated: 'I didn't realise how badly I hurt until the pain was gone.' The cost would reach about US$500 a month if she bought the drug from Novo, which recently introduced one-off discounts. After a week, Spencer said, her blood pressure dropped so low she thought she might pass out, so she stopped taking hypertension medicine. Her pressure stabilised and she lost three pounds. She wanted to understand more about microdosing, and turned to the grey market last summer. On Reddit, users told how another Novo drug in development, called CagriSema, had helped reduce inflammation and hunger pangs better than semaglutide. CagriSema is Novo's next-generation obesity drug candidate, still in clinical trials so not available to the public. It combines semaglutide with another molecule, called cagrilintide, which intensifies the hormone-mimicking effects to regulate blood sugar and reduce hunger. Spencer was intrigued. She found a US reseller saying they tested Chinese-made CagriSema through a third-party lab before selling it to Americans. On microdoses of CagriSema, Spencer could enjoy food in small quantities. 'I could say 'yes' because I knew I was only going to eat four bites.' In October, Spencer saw on Reddit that tirzepatide might also reduce inflammation. She placed a new order for vials that contained cagrilintide and tirzepatide combined, dubbed 'cagri-tirz.' Now each Monday, Spencer injects herself with tiny amounts of cagri-tirz. On Thursdays, she uses retatrutide, a new obesity medicine by Lilly, also in trials. As she was switching to cagri-tirz, Spencer made a dangerous mistake. She calculated her new dosage without realising the concentration of cagrilintide in the combined vials was 10 times higher than she had taken previously. 'I was an idiot. I didn't do my math. Or rather, I did the math for the tirzepatide but not for the cagri,' she said. Almost immediately, she began vomiting. The reaction was so severe she had trouble moving. She forced herself to drink water but couldn't eat. After four days, when symptoms lifted, she had lost seven pounds. Despite the blunder, Spencer didn't consider returning to compounded versions of the drugs or abandoning them altogether. She is not regularly monitored by a healthcare provider, but says her treatment has led to a 'life-changing' reduction in weight, joint pain and blood pressure. Marie, who asked to be identified by her middle name, filters reconstituted obesity medication, which was purchased through the grey market, a new market that allows consumers to purchase obesity medication materials from China and reconstitute them into injectable drugs, in the US Midwest April 28, 2025. — Reuters pic 'Honour system' Grey-market buyer Marie, 41, shows how do-it-yourself drugmakers are organising. She describes herself as a 'football mom' from the Midwest and asked to be identified by her middle name to protect her privacy. Last year she bought a compounding pharmacy's version of tirzepatide, paying about US$470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs. She began to worry about her supply. Browsing on Reddit, she discovered links to Telegram and a trove of detailed instructions from experienced users for buying weight-loss drug ingredients from China. Customers said they often paid with Bitcoin or through mobile payment service Venmo. After a month closely following the forums, Marie made a purchase in January. The package that arrived contained 20 small glass vials of white powder with red caps. There were no instructions. The vendor who advertised the package on Telegram said it came from China. Marie returned to the forums and joined a group of 52 other customers who paid a total of US$1,020 to a Tennessee-based company called Peptide Test. Six members mailed in a vial each and the others chipped in their share of the fee. The lab found the samples were pure. Peptide Test declined to comment. 'It's an honour system,' said Marie. 'These groups are very supportive in a way I haven't seen on the internet before.' Marie, who asked to be identified by her middle name, stores obesity medication, which was purchased through the grey market, a new market that allows consumers to purchase obesity medication materials from China and reconstitute them into injectable drugs, in a deep freezer, in the US Midwest April 28, 2025. — Reuters pic Before her first injection, Marie gave her husband details of what she had done. They agreed that if needed, he would disclose everything to the emergency medics. But she was fine. In March, Marie volunteered to organise testing a new order of tirzepatide. The group formed on Telegram after users received vials from the same vendor which they judged to be from the same batch based on the colour of the caps. In all, 38 buyers agreed to chip in for the US$1,300 bill, and decided by poll that five vials would be enough. Five people sent drugs to the lab, Janoshik Analytical in the Czech Republic, which found the vials contained tirzepatide, as purported, with purity between 99.78 per cent and 99.85 per cent. Janoshik's CEO, Peter Magic, is a former amateur weight-lifter. He said his company started out more than a decade ago testing performance-enhancing drugs for online buyers. Last year, it tested 3,050 samples of obesity drugs, up from just over 650 samples in 2023. 'We're testing hundreds of these every week,' said Magic, whose company helps customers navigate customs requirements for shipping chemicals. — Reuters
